Coherus Oncology, Inc. (CHRS) Net income 2016–2025
Coherus Oncology, Inc. (CHRS) annual net income history from SEC filings — each fiscal year as reported, with year-over-year change.
$168.0MFY2025 · since FY2016: -$127.3M → $168.0M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $168.0M | +489.4% |
| FY2024 | $28.5M | +112.0% |
| FY2023 | -$237.9M | +18.5% |
| FY2022 | -$291.8M | -1.6% |
| FY2021 | -$287.1M | -317.1% |
| FY2020 | $132.2M | +47.2% |
| FY2019 | $89.8M | +142.9% |
| FY2018 | -$209.3M | +12.1% |
| FY2017 | -$238.2M | -87.0% |
| FY2016 | -$127.3M | — |
Source: SEC XBRL filings · For reference only · Not investment advice